Consistent Revenue GrowthFuji Pharma's multi-year consistent revenue growth, including a notable increase in the latest period, supports durable demand for its marketed drugs and contract manufacturing services. Predictable top-line expansion enhances the firm's ability to fund R&D, scale production, and broaden distribution over the medium term.

Improved Free Cash FlowReported improvements in free cash flow and positive FCF growth indicate stronger cash generation capacity. Sustained free cash flow allows Fuji Pharma to fund capex, support selective business development or dividends, and reduce dependence on external financing, bolstering long-term financial flexibility.

Focused Women's-health Franchise And CDMO CapabilitiesA niche focus on women's health combined with in‑house contract manufacturing positions Fuji Pharma with differentiated products and recurring institutional relationships. This specialization can create durable competitive advantages via regulatory know‑how, long-term supply contracts and higher customer stickiness.

Bears Say

Margin Volatility And Recent DeclinesRecent volatility and declines in EBIT and net profit margins reduce earnings predictability and compress internal funding for growth. Persistent margin pressure from pricing, reimbursement shifts or rising input costs would constrain free cash flow and limit the company's ability to reinvest or buffer against shocks.

Rising LeverageAn increasing debt‑to‑equity ratio elevates interest and refinancing risk and narrows strategic flexibility. Higher leverage can force tighter capital allocation, raise funding costs, and reduce capacity to pursue M&A or expand R&D if operating performance weakens or macro conditions tighten.

Weaker Operating Cash ConversionOperating cash flow lagging reported earnings implies weaker cash conversion. If persistent, this shortfall may require external financing to cover working capital or investment needs, undermining the benefits of improved free cash flow and constraining sustainable funding for R&D, dividends, or debt reduction.

Fuji Pharma Co., Ltd. News

Fuji Pharma Lifts Sales Outlook but Slashes Profit Forecast on Alvotech Valuation Loss

Fuji Pharma Co., Ltd. ( ($JP:4554) ) has issued an announcement. Fuji Pharma revised its earnings forecasts for...

28d ago

Fuji Pharma Books ¥2.46 Billion Securities Valuation Loss on Alvotech Stake

Fuji Pharma Co., Ltd. ( ($JP:4554) ) has issued an announcement. Fuji Pharma has recognized an impairment loss...

28d ago

Fuji Pharma Completes Stock Acquisition Rights Cancellation

The latest update is out from Fuji Pharma Co., Ltd. ( ($JP:4554) ). Fuji Pharma Co., Ltd. has...

7M ago

Fuji Pharma to Acquire and Cancel Stock Acquisition Rights

Fuji Pharma Co., Ltd. ( ($JP:4554) ) has issued an update. Fuji Pharma Co., Ltd. has resolved to...

8M ago

FUP FAQ

What was Fuji Pharma Co., Ltd.’s price range in the past 12 months?

Fuji Pharma Co., Ltd. lowest stock price was €7.25 and its highest was €13.10 in the past 12 months.

What is Fuji Pharma Co., Ltd.’s market cap?

Fuji Pharma Co., Ltd.’s market cap is €311.87M.

When is Fuji Pharma Co., Ltd.’s upcoming earnings report date?

Fuji Pharma Co., Ltd.’s upcoming earnings report date is May 12, 2026 which is in 68 days.

How were Fuji Pharma Co., Ltd.’s earnings last quarter?

Fuji Pharma Co., Ltd. released its earnings results on Feb 05, 2026. The company reported €0.073 earnings per share for the quarter, beating the consensus estimate of N/A by €0.073.

Is Fuji Pharma Co., Ltd. overvalued?

According to Wall Street analysts Fuji Pharma Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Fuji Pharma Co., Ltd. pay dividends?

Fuji Pharma Co., Ltd. does not currently pay dividends.

What is Fuji Pharma Co., Ltd.’s EPS estimate?

Fuji Pharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Fuji Pharma Co., Ltd. have?

Fuji Pharma Co., Ltd. has 24,891,100 shares outstanding.

What happened to Fuji Pharma Co., Ltd.’s price movement after its last earnings report?

Fuji Pharma Co., Ltd. reported an EPS of €0.073 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 17.647%.

Which hedge fund is a major shareholder of Fuji Pharma Co., Ltd.?

Currently, no hedge funds are holding shares in DE:FUP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Fuji Pharma Co., Ltd.

Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.